Skip to content
Smart Money

Pharmaceuticals

BFBIO BF Biosciences Limited

Latest results: FY2026 · Jun 2026

Last close · 16 Oct 2026

Rs 128.65 -0.96%

Annual · FY2020 – FY2026

BF Biosciences Limited (BFBIO) cash flow statement

BFBIO cash flow statement (annual) (Rs mn)
Rs mn FY2026 Jul 2025 – Jun 2026 FY2025 Jul 2024 – Jun 2025 FY2024 Jul 2023 – Jun 2024 FY2023 Jul 2022 – Jun 2023 FY2022 Jul 2021 – Jun 2022 FY2021 Jul 2020 – Jun 2021 FY2020 Jul 2019 – Jun 2020
Operating activities
Profit (cash-flow starting line, as reported) — 447.1 385.4 202.2 348.8 645.6 59.9
Depreciation & amortisation — 193.6 36.1 34.3 28.3 23.4 22.4
Net cash from operating activities — 282.6 519.5 (232.9) 292.0 583.7 (12.0)
Investing activities
Capital expenditure — (329.5) (143.1) (1,970.0) (1,130.2) (941.1) (22.2)
Net cash from investing activities — (1,430.1) (30.1) (807.8) (1,602.0) (1,376.8) (14.3)
Financing activities
Borrowings raised / (repaid) — (342.6) (321.4) 760.5 950.6 1,185.8 7.0
Net cash from financing activities — 1,512.6 (321.4) 760.5 950.6 1,185.8 7.0
Net change in cash — 365.0 168.0 (280.3) (359.4) 392.7 (19.3)
Key figures
Free cash flow (operating cash flow − capex) — (46.9) 376.4 (2,203.0) (838.1) (357.4) (34.2)
BFBIO cash flow statement — year-on-year change (Rs mn)
Rs mn FY2026 Jul 2025 – Jun 2026 FY2025 Jul 2024 – Jun 2025 FY2024 Jul 2023 – Jun 2024 FY2023 Jul 2022 – Jun 2023 FY2022 Jul 2021 – Jun 2022 FY2021 Jul 2020 – Jun 2021 FY2020 Jul 2019 – Jun 2020
Operating activities
Profit (cash-flow starting line, as reported) — +16.0% +90.6% -42.0% -46.0% +977.1% —
Depreciation & amortisation — +436.0% +5.2% +21.2% +20.9% +4.8% —
Net cash from operating activities — -45.6% — -179.8% -50.0% — —
Investing activities
Capital expenditure — +130.2% -92.7% +74.3% +20.1% +4,137.9% —
Net cash from investing activities — — — — — — —
Financing activities
Borrowings raised / (repaid) — — -142.3% -20.0% -19.8% +16,840.1% —
Net cash from financing activities — — -142.3% -20.0% -19.8% +16,840.1% —
Net change in cash — +117.3% — — -191.5% — —
Key figures
Free cash flow (operating cash flow − capex) — -112.5% — — — — —

Change against the previous fiscal year; shown when the earlier figure is positive.

Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets; "—" = not reported. Updated 16 Oct 2026.

All reported line items 51
BFBIO cash flow statement — all reported line items (Rs mn)
Rs mn FY2026 Jul 2025 – Jun 2026 FY2025 Jul 2024 – Jun 2025 FY2024 Jul 2023 – Jun 2024 FY2023 Jul 2022 – Jun 2023 FY2022 Jul 2021 – Jun 2022 FY2021 Jul 2020 – Jun 2021 FY2020 Jul 2019 – Jun 2020
Profit/(Loss) - Starting Line - Cash Flow — 447.1 385.4 202.2 348.8 645.6 59.9
Non-cash Items & Reconciliation Adjustments - Cash Flow — 486.9 390.7 96.2 (69.6) 29.0 17.5
Income Tax Expense - Cash Flow - to Reconcile — 273.4 190.2 — — — —
Other Non-Cash Items & Reconciliation Adjustments - Cash Flow - to Reconcile — 21.0 36.2 4.9 (19.4) 20.9 5.4
Financial Income/(Expense) - Cash Flow - to Reconcile — 29.0 130.5 66.9 (73.4) (11.7) (8.2)
Depreciation, Depletion & Amortization including Impairment - Cash Flow - to Reconcile — 193.6 36.1 34.3 28.3 23.4 22.4
Depreciation & Depletion - Property, Plant & Equipment - Cash Flow - to Reconcile — 191.9 35.6 33.8 28.3 23.4 22.4
Amortization - Intangible Assets & Deferred Charges - Cash Flow - to Reconcile — 1.7 0.6 0.6 — — 0.0
Assets Sale - Gain/(Loss) - Cash Flow - to Reconcile — (27.8) (2.4) (9.0) (3.3) (3.2) (0.4)
Financial Assets - Unrealized Gain/(Loss) - Cash Flow - to Reconcile — (2.3) 0.1 (1.0) (1.8) (0.4) (1.6)
Income Taxes - Paid/(Reimbursed) - Cash Flow — 279.1 51.4 92.8 60.0 31.6 36.5
Interest Paid - Cash — 112.2 161.5 120.3 25.1 23.3 1.2
Interest & Dividends - Received - Total - Cash Flow — 95.0 19.3 83.4 139.0 37.0 9.4
Cash Flow from Operating Activities before Changes in Working Capital — 637.8 582.5 168.6 333.1 656.7 49.2
Working Capital - Increase/(Decrease) - Cash Flow — (355.2) (63.0) (401.6) (41.1) (73.0) (61.2)
Accounts Receivables - Decrease/(Increase) - Cash Flow — (50.5) (122.7) (40.1) 161.7 (159.5) (15.8)
Inventories - Decrease/(Increase) - Cash Flow — (846.4) (41.6) (445.7) (50.4) (119.8) (65.3)
Other Assets - Decrease/(Increase) - Cash Flow — 74.6 (115.2) 108.0 (175.8) 93.2 (105.2)
Accounts Payable and Accrued Expenses - Increase/(Decrease) - Cash Flow — 472.4 196.8 (5.9) 12.5 107.6 125.1
Other Liabilities - Increase/(Decrease) -Total - Cash Flow — (5.3) 19.7 (17.8) 10.9 5.6 —
Net Cash Flow from Operating Activities — 282.6 519.5 (232.9) 292.0 583.7 (12.0)
Capital Expenditures - Net - Cash Flow — 325.6 138.7 1,969.0 1,125.9 938.2 21.6
Property, Plant & Equipment - Purchased/(Sold) - Net - Cash Flow — 325.6 138.7 1,967.3 1,125.9 938.2 21.6
Property, Plant & Equipment - Purchased - Cash Flow — 329.5 143.1 1,968.4 1,130.2 941.1 22.2
Property, Plant & Equipment Sold - Cash Flow — 3.9 4.4 1.1 4.3 2.9 0.7
Intangible Assets - Purchased/(Sold) - Net - Total - Cash Flow — — 0.0 1.7 — — —
Intangible Assets - Purchased/Acquired - Cash Flow — — 0.0 1.7 — — —
Capital Expenditures - Total — 329.5 143.1 1,970.0 1,130.2 941.1 22.2
Investments excluding Loans - Decrease/(Increase) - Cash Flow — (1,100.4) 108.6 1,161.1 (476.1) (438.3) 7.3
Investment Securities - Unclassified - Sold/(Purchased) - Net - Total - Cash Flow — (1,100.4) 108.6 1,161.1 (476.1) (438.3) 7.3
Other Investing Cash Flow - Decrease/(Increase) — (4.0) — — 0.0 (0.3) —
Net Cash Flow from Investing Activities — (1,430.1) (30.1) (807.8) (1,602.0) (1,376.8) (14.3)
Debt - Long-Term & Short-Term - Issuance/(Retirement) - Total - Cash Flow — (342.6) (321.4) 760.5 950.6 1,185.8 7.0
Debt - Issued/Reduced - Long-Term - Cash Flow — (342.6) (321.4) 760.5 950.6 1,185.8 7.0
Debt - Issued - Long-Term - Cash Flow — 93.6 0.0 811.0 968.1 1,194.6 7.0
Debt - Reduced - Long-Term - Cash Flow — 436.2 321.4 50.5 17.5 8.8 —
Other Financing Cash Flow - Increase/(Decrease) — 1,855.2 — — — — —
Net Cash Flow from Financing Activities — 1,512.6 (321.4) 760.5 950.6 1,185.8 7.0
Net Change in Cash - Total — 365.0 168.0 (280.3) (359.4) 392.7 (19.3)
Net Cash from Continuing Operations — 365.0 168.0 (280.3) (359.4) 392.7 (19.3)
Net Cash - Beginning Balance — (49.9) (217.9) 62.3 421.7 29.0 48.2
Net Cash - Ending Balance — 315.1 (49.9) (217.9) 62.3 421.7 29.0
Income Taxes - Paid/(Reimbursed) - Cash Flow - Supplemental — 279.1 51.4 92.8 60.0 31.6 36.5
Interest Paid - Cash Flow - Supplemental — 112.2 161.5 120.3 25.1 23.3 1.2
Interest & Dividends - Received - Cash Flow - Supplemental — 95.0 19.3 83.4 139.0 37.0 9.4
CF from Optg Activities before Change in WC & Int Payments — 750.0 744.0 288.9 358.2 680.0 50.3
Contract Liabilities - Increase/(Decrease) - Cash Flow — (5.3) 19.7 (17.8) 10.9 5.6 —
Depreciation, Depletion & Amortization - Cash Flow — 193.6 36.1 34.3 28.3 23.4 22.4
Free Cash Flow to Equity — (385.7) 59.4 (1,441.4) 116.7 831.3 (26.5)
Free Cash Flow Net of Dividends — (46.9) 376.4 (2,203.0) (838.1) (357.4) (34.2)
Free Cash Flow — (46.9) 376.4 (2,203.0) (838.1) (357.4) (34.2)

Every line the company reported, in the original order and wording, without regrouping or signs changed. Latest 7 periods; the table above goes back further.